Related Experiment Video
Updated: Jun 18, 2026
08:15
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Second messenger modulation: a novel target of future antidepressants?
D Marazziti1, M Catena Dell'Osso, G Consoli
1Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie, University of Pisa, 56100 Pisa, Italy. dmarazzi@psico.med.unipi.it
Current Medicinal Chemistry
|November 12, 2009
Summary
G protein-coupled receptors (GPCRs) are crucial for cellular signaling and mood regulation. Understanding GPCR pathways offers new therapeutic avenues for mood disorders.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- G protein-coupled receptors (GPCRs) mediate cellular responses to extracellular signals.
- GPCRs regulate key signaling molecules like second messengers.
- Alterations in GPCR activity are implicated in mood disorders.
Purpose of the Study:
- To review signal transduction pathways activated by brain metabotropic receptors.
- To explore the involvement of these pathways in mood disorder pathophysiology.
- To highlight innovative therapeutic strategies targeting GPCRs.
Main Methods:
- Literature review of GPCR signaling pathways.
- Analysis of GPCR involvement in mood disorder mechanisms.
- Exploration of therapeutic potential of GPCR modulation.
Main Results:
- GPCRs modulate enzymes and ion channels, impacting second messenger levels.
- These pathways trigger biochemical cascades, including calcium release and gene expression.
- Monoamine GPCRs are significantly altered in mood disorders, with antidepressants acting via these systems.
Conclusions:
- Metabotropic receptor signaling pathways in the brain are central to mood regulation.
- Dysregulation of these pathways contributes to mood disorder development.
- Targeting GPCRs presents promising innovative therapeutic strategies for mood disorders.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:15Amplifying Signals via Second Messengers
Many receptor binding ligands are hydrophilic; they do not cross the cell membrane but bind to cell-surface receptors. Thus, their message must be relayed by second messengers present in the cell cytoplasm. There are several second messenger pathways, each with its own way of relaying information. For example, the G protein-coupled receptors can activate both phosphoinositol and cyclic AMP (cAMP) second messenger pathways. The phosphoinositol pathway is active when the receptor induces...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:26Neurochemical Transmission: Sites of Drug Action
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...